Chelohart
Research OnlyA cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
Mostly preclinical · 1 human study
- Preclinical
- 80%
- Clinical
- 20%
Based on 5 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 15: the only Chelohart-specific study (PMID 26390619) is an in-vitro organotypic rat heart-tissue culture (1A=6 animal/in-vitro tier, 1B=2 high RoB, 1C=1 human N<50, 1D=2 indirect surrogate, 1E=4 modest preclinical program); the dossier's "1 human study" has no resolvable PMID and no human RCT exists. Mechanism 30: undefined tissue extract with target only inferred via the Khavinson DNA-promoter framework (2A=10), proximal proliferation signaling partly characterized — PCNA up / p53 down in heart cultures, 26390619 (2B=9), single-model dose-response 20-50 ng/ml (2C=6), ex-vivo mammalian confirmation (2D=5). Plausibility 50: mechanism->cardiac benefit rests on >=1 unproven link (oral bioavailability, surrogate proliferation -> clinical cardiac health) (3A=16), coherent with tissue-peptide biology (3B=14), class analogy from other Khavinson tissue-specific tetrapeptides incl. heart-peptide design (PMID 12374906, 3C=11), tightly scoped to cardiac tissue (3D=9). Global Coverage 12: all work from the single St. Petersburg Institute group, no independent replication (4A=4, 4B=4), <5 studies (4C=4), no regulator review (4D=0). Community Experience 14: dossier reports no meaningful community discussion (5A=3), cytamin-class sold for years but no Chelohart-specific track record (5B=7), nothing to assess consistency (5C=0), no documented adverse signal over limited exposure (5D=4). Effectiveness not-established: no quantified human efficacy estimate and no meaningful community effect signal. Cardiac gene-expression mechanism support: Vilon/Epithalon (PMID 12360356) and Cortagen (PMID 15159690) alter mouse-heart transcriptome; Ki-67/MKI67 epigenetic regulation framework (PMID 25051766).
Mechanism of Action
Chelohart is a cytamin-class supplement containing peptide complexes derived from cardiac (heart) tissue of young animals. It belongs to the Khavinson bioregulatory peptide framework developed at the St. Petersburg Institute of Bioregulation and Gerontology.
Proposed Mechanisms
- Myocardial Support — Claimed to contain tissue-specific peptides that support cardiac muscle cell function and metabolism
- Cardiac Tissue Regulation — Proposed bioregulatory effects on cardiac tissue gene expression via short peptide signaling
- Cardioprotection — Marketed for age-related cardiac support within the Khavinson bioregulator framework
How Cytamins Work (Theoretical)
Cytamins are oral supplements containing tissue-specific peptide complexes extracted from animal organs. The Khavinson theory proposes that these short peptides (2-4 amino acids) survive digestion, reach target tissues, and regulate gene expression by interacting with DNA promoter regions. This mechanism remains unvalidated by Western research standards.
Relationship to Cardiogen
Chelohart (tissue-derived cytamin) and Cardiogen (synthetic AED tripeptide) both target cardiac tissue within the Khavinson system. Cardiogen represents the synthetic, defined-sequence approach while Chelohart is the tissue extract complex. They are often marketed as complementary products.
Important Limitations
- NOT a defined peptide — contains complex mixture of tissue-derived peptides
- Oral peptide bioavailability is generally very low
- No Western clinical validation or independent replication
- No randomized controlled trials meeting international standards
- NOT a treatment for heart disease or any cardiac condition
- Not approved by any Western regulatory agency
- Primarily supported by Russian-language literature from a single research group
Cardiogen
CompatibleBoth target cardiac function within the Khavinson framework. Cardiogen is a synthetic AED tripeptide while Chelohart is a tissue-derived cytamin supplement. Often marketed together for cardiac support.
Vesugen
CompatibleBoth target cardiovascular system — Vesugen is synthetic KED tripeptide for vascular endothelium, Chelohart is tissue-derived for cardiac muscle.
Ventfort
CompatibleComplementary cardiovascular targets — Ventfort for blood vessels, Chelohart for heart tissue. Both are cytamin-class supplements.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Chelohart
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01 · Evaxion EVX-01 · AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1/2 data in melanoma showed a 67% objective response rate (8/12; 6 partial, 2 complete) when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.
Livagen
KED · Lys-Glu-Asp · Hepatogen
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.